Osteoporosis

U.S. FDA approves Fortical for postmenopausal osteoporosis

Published in Women's Health Weekly, September 15th, 2005

Unigene Laboratories, Inc., (UGNE) has received approval from the U.S. Food and Drug Administration (FDA) for Fortical calcitonin-salmon (rDNA origin) Nasal Spray, its nasal calcitonin product for the treatment of postmenopausal osteoporosis.

FDA approval triggers the final milestone payment of $4 million under Unigene's exclusive U.S. licensing agreement with Upsher-Smith Laboratories, Inc.

Fortical will be manufactured at Unigene's production facility in Boonton, New Jersey. The final product will be packaged, marketed, and sold in the United States by Upsher-Smith. Unigene will sell the filled product to Upsher-Smith and receive royalties on...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2005-09-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry